New drug aticaprant tested as Add-On for schizophrenia

NCT ID NCT07615426

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage trial tests whether the experimental drug aticaprant is safe and tolerable when added to standard antipsychotic treatment for schizophrenia. About 64 clinically stable outpatients will receive either aticaprant or a placebo. The main goals are to see if the study is feasible and to monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aticaprant (JNJ-67953964)
What this could lead to: If successful, this could point toward a new add-on treatment option for schizophrenia that is safe and tolerable.
What could go wrong: This is a very early Phase 1b trial with only 64 participants, focused on safety and feasibility, not on how well the drug works. Many drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

CNS Network
RECRUITING

Garden Grove, California, 92845, United States
Community Clinical Research, Inc.
RECRUITING

Austin, Texas, 78754, United States
Evolution Research Group
RECRUITING

Staten Island, New York, 10314, United States
Neurobehavioral Research Inc
RECRUITING

Cedarhurst, New York, 11516, United States
Pillar Clinical Research, LLC
RECRUITING

Richardson, Texas, 75080, United States
Synexus Clinical Research US Inc
RECRUITING

Atlanta, Georgia, 30328, United States
Uptown Research Institute
RECRUITING

Chicago, Illinois, 60640, United States
Western Michigan University
RECRUITING

Kalamazoo, Michigan, 49008, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.